Lilian Stern is Principal at Stern IR, Inc., a consulting firm specializing in investor relations services for biotechnology companies. She founded Stern IR to provide differentiated investor relations and communications consulting to the healthcare industry, with a particular focus on biotechnology, including specialty pharmaceuticals, innovative diagnostics and tools, and vaccines. She has initiated and participated in some of the firm's key accomplishments including working with the team to represent over 500 companies during Stern IR's tenure and rolling out and positioning many multibillion-dollar M&A transactions. Stern holds an A.B. from Cornell University in molecular biology and biochemistry where she was a college scholar and holds a J.D. from Harvard Law School.
